Drug-coated balloon combined with drug-eluting stent for the treatment of coronary bifurcation lesions: insights from the HYPER study. (26th April 2023)

• Record Type: Journal Article
• Authors: Pellegrini, Dario; Donahue, Michael; Regazzoli, Damiano; Tedeschi, Delio; Loffi, Marco; Pellicano, Mariano; De Blasio, Giuseppe; Tespili, Maurizio; Guagliumi, Giulio; Ielasi, Alfonso
• Is Part Of: European heart journal supplements. Volume 25(2023)Supplement C
• Page Start: C79
• Page End: C83
• Publication Date: 2023-04-26
• Subjects: Coronary artery disease -- Percutaneous coronary intervention -- Hybrid approach -- Drug-eluting stent -- Drug-coated balloon -- Small vessel disease -- Bifurcation lesion -- Coronary stenosis -- Coronary revascularization; Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suad011
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: True coronary bifurcation lesions (CBL) represent a challenging scenario for percutaneous coronary interventions (PCI), and are associated with a higher risk of target lesion failure (TLF), particularly when two stents are implanted. A hybrid strategy combining a drug-eluting stent (DES) in the main branch, and a drug-coated balloon in the side branch may improve outcomes by reducing the total stent length while maintaining an effective anti-prolipherative action. In this sub-study of the HYPER trial, 50 patients with true CBL were treated with a hybrid strategy: procedural success was 96%, one case of peri-procedural myocardial infarction and one case of TLF (in a DES-treated segment) at 1 year were reported. This study suggests that such a hybrid strategy may be a safe and effective option for true CBL PCI, and warrants additional investigations to compare outcomes with standard of care strategies.